Valent P, Horny HP, Triggiani M, Arock M. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. International archives of allergy and immunology. 2011 May 16;156(2):119-27.

Afrin LB. The presentation, diagnosis and treatment of mast cell activation syndrome. Curr Allergy Clin Immunol. 2014 Sep;27:146-60.

Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Current allergy and asthma reports. 2013 Feb 1;13(1):10-8.

Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011 Mar 22;4(10).

Molderings GJ, Homann J, Brettner S, Raithel M, Frieling T. Systemische Mastzellaktivierungserkrankung: Ein praxisorientierter Leitfaden zu Diagnostik und Therapie. DMW-Deutsche Medizinische Wochenschrift. 2014 Jul;139(30):1523-38.

Afrin LB, Molderings GJ. A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol. 2014 Feb;3(1):1-7.

Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M, Jones N, Lindsley A, Komarow HD, Bai Y, Scott LM. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. The Journal of allergy and clinical immunology. 2014 May;133(5):1471.

Sido B, Dumoulin FL, Homann J, Hertfelder HJ, Bollmann M, Molderings GJ. Chirurgische Eingriffe an Patienten mit Mastzellüberaktivitätserkrankung. Der Chirurg. 2014 Apr 1;85(4):327-33.

Pöhlau D, Raithel M, Haenisch B, Harzer S, Molderings G. Neurologische und psychiatrische Symptome der systemischen MCAD. Springer Medizin2015 Sep; NeuroTransmitter

Emergency room protocol

Mastocytosis Society

http://www.tmsforacure.org/documents/ER_Protocol.pdf

Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008 Feb 1;63(2):226-32.

Molderings GJ, Kolck U, Scheurlen C, Brüss M, Frieling T, Raithel M, Homann J. Die systemische Mastzellerkrankung mit gastrointestinal betonter Symptomatik–eine Checkliste als Diagnoseinstrument. Dtsch Med Wochenschr. 2006 Sep;131:2095-100.

Brockow K, Metcalfe DD. Mastocytosis. Current opinion in allergy and clinical immunology. 2001 Oct 1;1(5):449-54.

Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, Valent P, Akin C. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. The Journal of Allergy and Clinical Immunology: In Practice. 2014 Feb 28;2(1):70-6.

Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. PloS one. 2013 Sep 30;8(9):e76241.

Afrin LB. Mast cell activation syndrome as a significant comorbidity in sickle cell disease. The American journal of the medical sciences. 2014 Dec 31;348(6):460-4.

Alevizos M, Karagkouni A, Panagiotidou S, Vasiadi M, Theoharides TC. Stress triggers coronary mast cells leading to cardiac events. Annals of Allergy, Asthma & Immunology. 2014 Apr 30;112(4):309-16.

Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. PloS one. 2013 Sep 30;8(9):e76241.

Vysniauskaite M, Hertfelder HJ, Oldenburg J, Dreßen P, Brettner S, Homann J, Molderings GJ. Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease. PloS one. 2015 Apr 24;10(4):e0124912.

Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime?. Immunology. 2014 Mar 1;141(3):314-27.

Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013 Apr 1;68(4):417-24.

Afrin LB, Pöhlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain, behavior, and immunity. 2015 Nov 30;50:314-21.

Afrin LB, Khoruts A. Mast cell activation disease and microbiotic interactions. Clinical therapeutics. 2015 May 1;37(5):941-53.

Molderings GJ. The genetic basis of mast cell activation disease-looking through a glass darkly. Critical reviews in oncology/hematology. 2015 Feb 28;93(2):75-89.

Kolck UW, Haenisch B, Molderings GJ. Cardiovascular symptoms in patients with systemic mast cell activation disease. Translational Research. 2015 Dec 28.

Frieri M, Patel R, Celestin J. Mast cell activation syndrome: a review. Current allergy and asthma reports. 2013 Feb 1;13(1):27-32.

Afrin LB. Mast Cell Activation Disease and the modern Epidemic of Chronic Inflammatory Disease. Translational Research. 2016 Jan 18.

Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. The Journal of Allergy and Clinical Immunology: In Practice. 2014 Dec 31;2(6):775-8.

Afrin LB., Neilsen Myles K., Posival K. Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media LLC; 1 edition (March 15, 2016)

PETRA, Anastasia I., et al. Spectrum of mast cell activation disorders. Expert review of clinical immunology, 2014, 10. Jg., Nr. 6, S. 729-739.

VYSNIAUSKAITE, Milda, et al. Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease. PloS one, 2015, 10. Jg., Nr. 4, S. e0124912.

AFRIN, Lawrence B., et al. Often seen, rarely recognized: mast cell activation disease–a guide to diagnosis and therapeutic options. Annals of medicine, 2016, 48. Jg., Nr. 3, S. 190-201.

CACABELOS, Ramón, et al. Histamine and Immune Biomarkers in CNS Disorders. Mediators of inflammation, 2016, 2016. Jg.

XU, Yunzhi; CHEN, Guangjie. Mast cell and autoimmune diseases. Mediators of inflammation, 2015, 2015. Jg.

HART, David A. Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted?. International journal of inflammation, 2015, 2015. Jg.

SKAPER, Stephen D.; FACCI, Laura. Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Phil. Trans. R. Soc. B, 2012, 367. Jg., Nr. 1607, S. 3312-3325.

WENG, Zuyi, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One, 2012, 7. Jg., Nr. 3, S. e33805.

BONAMICHI-SANTOS, Rafael; CASTELLS, Mariana. Mast Cell Activation Syndromes. Current Treatment Options in Allergy, S. 1-17.

Einer meiner Artikel zu MCAS (DEUTSCH):

https://www.mta-dialog.de/artikel/das-mastzellaktivierungssyndrom.html